Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Medicine (Baltimore) ; 103(17): e37914, 2024 Apr 26.
Artículo en Inglés | MEDLINE | ID: mdl-38669418

RESUMEN

RATIONALE: Primary cardiac angiosarcoma (PCA) is a rare and fatal disease with a poor prognosis. Whether the survival of PCA patients can be prolonged with additional treatment following complete surgical excision is controversial. PATIENT CONCERNS: In this case study, a 52-year-old male complained of chest tightness and pain for 7 days before admission into the hospital. Subsequently, he revisited the hospital because of dizziness and headache. DIAGNOSES: Initially, the patient was diagnosed with PCA in the right atrium by thoracic computed tomography (CT). Palliative resection identified brain, lung, and liver metastases. INTERVENTION: The patient accepted multimodal combination therapy, including first-line chemotherapy and then second-line anlotinib concurrent with brain radiotherapy and immunotherapy. OUTCOME: Although anlotinib combined with brain radiotherapy controlled the growth of intracranial lesions, progression-free survival (PFS) was only 5 months, and the overall survival (OS) was only 12 months. LESSON: The treatment for metastatic PCA needs an in-depth exploration.


Asunto(s)
Neoplasias Encefálicas , Neoplasias Cardíacas , Hemangiosarcoma , Indoles , Quinolinas , Humanos , Masculino , Persona de Mediana Edad , Quinolinas/uso terapéutico , Hemangiosarcoma/terapia , Hemangiosarcoma/patología , Neoplasias Cardíacas/secundario , Neoplasias Cardíacas/terapia , Neoplasias Encefálicas/secundario , Neoplasias Encefálicas/terapia , Indoles/uso terapéutico , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/terapia , Antineoplásicos/uso terapéutico , Terapia Combinada , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA